APA (7th ed.) Citation

Sato, N., Masuda, N., Morimoto, T., Ueno, T., Kanbayashi, C., Kaneko, K., . . . Toi, M. (2019). Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study. Wiley.

Chicago Style (17th ed.) Citation

Sato, Nobuaki, et al. Neoadjuvant Exemestane or Exemestane Plus Docetaxel and Cyclophosphamide Tailored by Clinicopathological Response to 12 weeks' Exemestane Exposure in Patients with Estrogen Receptor‐positive Breast Cancer: A Multicenter, Open‐label, Phase II Study. Wiley, 2019.

MLA (9th ed.) Citation

Sato, Nobuaki, et al. Neoadjuvant Exemestane or Exemestane Plus Docetaxel and Cyclophosphamide Tailored by Clinicopathological Response to 12 weeks' Exemestane Exposure in Patients with Estrogen Receptor‐positive Breast Cancer: A Multicenter, Open‐label, Phase II Study. Wiley, 2019.